{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.7"}]}],"title":"Cycle 1 Day 1 (Anti-E7777 Antibodies)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.7"}]}],"title":"Cycle 2 Day 1 (Anti-E7777 Antibodies)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.7"}]}],"title":"Cycle 3 Day 1 (Anti-E7777 Antibodies)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5"}]}],"title":"Cycle 1 Day 1 (Anti-IL-2 Antibodies)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.3"}]}],"title":"Cycle 2 Day 1 (Anti-IL-2 Antibodies)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.6"}]}],"title":"Cycle 3 Day 1 (Anti-IL-2 Antibodies)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"94"}],"units":"Participants"}],"description":"Immunogenicity was assessed by determining the anti-E7777 and anti-IL-2 antibodies in serum using validated methods. Percentage of participants testing positive for Anti-E7777 and Anti-IL-2 antibodies were reported.","groups":[{"description":"Participants were treated with E7777 9 mcg/kg by IV infusion over 60 minutes on 5 consecutive days in 21-day cycles for up to 8 cycles or disease progression or unacceptable toxicity in Lead-in part and in Main study part and were presented together here, as planned.","id":"OG000","title":"Main Study Part: E7777 9 mcg/kg"}],"paramType":"NUMBER","populationDescription":"Main Study Part PK Analysis Set included all participants from whom at least one quantifiable concentration of E7777 was observed at 9 mcg/kg dose (both Main Study and Lead-In).","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1, Cycle 2 Day 1, Cycle 3 Day 1","title":"Main Study Part: Percentage of Participants Testing Positive for Anti-E7777 and Anti-IL-2 Antibodies","type":"SECONDARY","unitOfMeasure":"percentage of participants"}